Anne Marzi,1 Kai Moritz Eder,1 Álvaro Barroso,1 Ane Marit Wågbø,2 Torkild Visnes,2 Ruth B. Schmid,2 Geir Klinkenberg,2 Björn Kemper,1 Jürgen Schnekenburger1
1Univ. of Muenster (Germany) 2SINTEF Industry (Norway)
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Digital holographic microscopy (DHM) has been demonstrated to be a suitable label-free and non-invasive quantitative phase imaging (QPI) tool in risk assessment of the cytotoxic potential of engineered nanoparticles and organic nanocarriers. For a broader application, robustness of DHM-based assays needs to be demonstrated towards DHM standardization in risk assessment. Thus, we performed an interlaboratory comparison on the transferability and reproducibility of a DHM-based assay. The cytotoxic potential of organic nanoparticles on A549 lung epithelial cells was analyzed in two European laboratories using identically constructed DHM systems. Our results demonstrate a solid and accurate performance of the DHM-based cytotoxicity assay
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Anne Marzi, Kai Moritz Eder, Álvaro Barroso, Ane Marit Wågbø, Torkild Visnes, Ruth B. Schmid, Geir Klinkenberg, Björn Kemper, Jürgen Schnekenburger, "Digital holographic microscopy for label-free in vitro cytotoxicity testing of polymeric nanocarriers: an interlaboratory comparison," Proc. SPIE 12389, Quantitative Phase Imaging IX, 123890F (16 March 2023); https://doi.org/10.1117/12.2649808